Ogalvibart | Interleukin Related interleukin-related.com

Product Name :
Ogalvibart

Search keywords :
Ogalvibart

drugId :
null

Target Vo:
Coronavirus spike glycoprotein

Target Vo Short Name :
S glycoprotein

Moa_Name:
Coronavirus spike glycoprotein inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
The Rockefeller University

Active Company_Name :
Bristol-Myers Squibb Company

Active Indication_Name:
Coronavirus Disease 2019 (COVID-19)

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 1 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
C5b-9 Antibody
PUMA Antibody
RUNX2 Antibody: RUNX2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 57 kDa, targeting to RUNX2. It can be used for ICC/IF,IHC-P,WB assays with tag free, in the background of Human, Mouse.

Author: Interleukin Related

Related Posts